| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | GnRH |
| Uniprot No | P01148 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-92aa |
| 氨基酸序列 | MKPIQKLLAGLILLTWCVEGCSSQHWSYGLRPGGKRDAENLIDSFQEIVK EVGQLAETQRFECTTHQPRSPLRDLKGALESLIEEETGQKKI |
| 预测分子量 | 36 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于GnRH重组蛋白的3篇示例文献(虚构内容，仅作参考格式示例)：
1. **文献名称**: "Efficient production of recombinant GnRH in Escherichia coli for clinical use"
**作者**: Smith A, et al.
**摘要**: 研究通过大肠杆菌表达系统高效生产重组GnRH蛋白，优化纯化工艺，验证其生物活性与天然GnRH一致，为大规模生产提供新方法。
2. **文献名称**: "Structural and functional analysis of a novel GnRH mutant variant expressed in yeast"
**作者**: Johnson R, et al.
**摘要**: 利用酵母表达系统合成GnRH突变体，解析其三维结构，揭示特定氨基酸残基对受体结合能力的影响，为靶向药物设计提供依据。
3. **文献名称**: "Recombinant GnRH-based therapy in ovarian cancer models"
**作者**: Zhang Y, et al.
**摘要**: 评估重组GnRH蛋白在卵巢癌动物模型中的治疗效果，证实其通过下调激素信号通路抑制肿瘤生长，提示潜在临床应用价值。
4. **文献名称**: "Comparative study of GnRH isoforms produced via mammalian cell expression systems"
**作者**: Lee H, et al.
**摘要**: 对比哺乳动物细胞(CHO细胞)表达的不同GnRH亚型重组蛋白的药代动力学特性，发现特定亚型在体内稳定性显著提升。
---
如需真实文献，建议通过PubMed或Google Scholar检索关键词：
`recombinant GnRH protein production/therapy/structure`，筛选近5年高被引研究。
Gonadotropin-releasing hormone (GnRH), a decapeptide neurohormone, plays a pivotal role in regulating reproductive physiology across vertebrates. First isolated in 1971. endogenous GnRH is secreted by hypothalamic neurons in pulsatile patterns to stimulate pituitary gonadotropin release, thereby controlling steroidogenesis, gametogenesis, and sexual maturation. Its critical function in the hypothalamic-pituitary-gonadal axis has driven extensive research into therapeutic applications.
The development of recombinant GnRH protein emerged alongside advances in genetic engineering and peptide synthesis technologies. Unlike synthetic analogs prone to structural variability, recombinant systems using E. coli, yeast, or mammalian cell cultures enable precise production of biologically active GnRH with consistent post-translational modifications. This approach gained momentum in the 1990s as biopharmaceutical demands increased for reproductive disorder treatments, including hypogonadism, infertility, and hormone-sensitive cancers.
Modern applications extend beyond native hormone replacement. Engineered GnRH variants fused with carrier proteins or conjugated to targeting moieties are being explored for improved pharmacokinetics and tissue-specific delivery. Additionally, recombinant GnRH serves as a critical component in veterinary reproductive management and aquaculture breeding programs. Recent research focuses on sustained-release formulations and GnRH-based vaccines for contraception and oncological therapies. The protein's versatility continues to inspire innovations in both clinical endocrinology and biotechnological development, though challenges remain in optimizing stability and delivery mechanisms for enhanced therapeutic efficacy.
×
